Healthcare Global Enterprises Limited

Hospital/Nursing Management/ NSE

Compiled

Auto-generated from filings and public channels — no analyst dossier.

If management delivers what it guided

arithmetic on filed guidance and past valuations · not a price target

HCG

FY26 → FY30 · 4 years of guidance · ~3.7 years from today₹671 today

BEAR

₹119

-82%-38% a yr

7.4% a year · 97.7x exit

BASE

₹203

-70%-28% a yr

12.7% a year · 136.4x exit

BULL

₹767

+14%+4% a yr

17.3% a year · 440x exit

Where the market has priced it

75x730x today — outside the range582x

the guided figure reached earnings through a low-confidence bridge
the last 3 years priced this company 28% above its ten-year median (175x vs 136x) — the exit multiple here is the ten-year one, so a sustained re-rating would not be captured
at 730x its FY26 earnings the stock already trades above the top of its own ten-year range (440x)
the range is unusually wide — read it as the span of management's own claim, not as a forecast
this company's own median multiple sits 157% above its filed-industry peers; the scenario uses its own

How these numbers are produced

Earnings base	FY26 fiscal year EPS ₹0.92 (screener)
Guided growth	12.7% a year, said on the call of 26-May-2026 · transcript
Read across as	operating: unlabelled growth figure, read as revenue — low confidence
Delivery calibration	0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings
Exit multiple	97.65x / 136.36x / 440x, this company’s own p20 / median / p80 across 7 filed years
Filed-industry peers	median 53.12x across 10 peers — the cross-check, not the input
Arithmetic	base EPS × (1 + guided growth × delivery)⁴ × exit multiple

Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.

How to read this

It answers one question. If this management delivers the growth it told its own investors it would, and the market pays what it has historically paid for this company's earnings, where does the arithmetic land? Nothing here is a forecast of the share price.
Three cases, two moving parts. Bear, base and bull vary the delivery — what fraction of guidance managements actually file — and the exit multiple together, because a company that misses its guidance is usually de-rated for missing it. Each case shows the growth rate and the multiple that produced it.
Read the width, not just the middle. A wide gap between bear and bull means the inputs are uncertain, not that the upside is bigger. A narrow range is a more confident statement than a high one.
“Where the market has priced it” puts today's P/E on the company's own historical range. Sitting far below that range is why a scenario can look enormous: the number is then mostly about re-rating, not about delivery, and the board marks those separately.
The bullets underneath are the caveats — a borrowed peer multiple, a thin filed history, an earnings base that carried a one-off. They are the reasons to trust the number less, listed rather than buried.

Not a price target, not a recommendation, and not a forecast of what the stock will do. The field guide covers the method.

What management said

from NSE earnings-call filings · extracted, not interpreted

generic growth 15%

And in the medium term, our estimate remains close to the 15% growth projections that we had given earlier.

Call 26-May-2026 · bridge confidence low · transcript PDF

Coverage

SectorHospital/Nursing Management

Dossiersnone

Guidanceyes

Scenarioyes

Street chatter

unverified · logged from public channels

*Morgan Stanley on Healthcare*

Rising NCD burden, bed shortages and fragmentation drive growth for corporate hospitals

Apollo targets mid-teens growth via expansion, clusters, integration

CDMO outlook remains strong with 15-20% revenue CAGR and ~28-30% margins, supported by capacity expansion, diversified pipelines and large-pharma part

Guidance04 Jun 03:21

HEXAWARE: Collaborates with HBSUK to deploy AI-driven healthcare workforce platform.

Mention only03 Jun 13:29

Expect hospitals will continue to see higher competition from Manipal for doctors

Prefer Fortis Healthcare and Apollo Hospitals; both are Buy-rated

Guidance02 Jul 03:26

📈 Sectoral Tailwinds

Demand in IT services, specialty chemicals, and positive outlooks for healthcare and water infrastructure are supporting gains.

31 Jul 04:30